Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 17/309% above fair value
$927.89+109.12 (+13.33%)
Close on Oct 30, 2026Market cap $95.53BP/E 20.5Yield –
Earnings
Regeneron Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Jan 29, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$5.10B
+36.0% on a year earlier
non-GAAP EPS, Q3 FY2026
$20.07
$11.83 a year earlier
Latest guidance
Raised
Oct 30, 2026 · 9 items
Quarterly results
Revenue and earnings per share from each of Regeneron Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 29, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 30, 2026before the open | $5.10B | +36.0% | $18.45 | $20.07 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026before the open | $4.30B | +16.8% | $12.23 | $14.29 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026before the open | $3.60B | +18.9% | $6.75 | $9.47 | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 30, 2026before the open | $3.90B | +2.9% | $7.86 | $11.44 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025before the open | $3.75B | +0.8% | $13.62 | $11.83 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 1, 2025before the open | $3.68B | +3.7% | $12.81 | $12.89 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025before the open | $3.03B | -3.8% | $7.27 | $8.22 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 4, 2025before the open | $3.79B | +10.5% | $8.06 | $12.07 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024before the open | $3.72B | +10.7% | $11.54 | $12.46 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024before the open | $3.55B | +12.3% | $12.41 | $11.56 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $3.15B | -0.3% | $6.27 | $9.55 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 2, 2024before the open | $3.43B | +0.6% | $10.19 | $11.86 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $3.36B | +14.4% | $8.89 | $11.59 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $3.16B | +10.6% | $8.50 | $10.24 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $3.16B | +6.6% | $7.17 | $10.09 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 3, 2023before the open | $3.41B | -31.1% | $10.50 | $12.56 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $2.94B | -15.0% | $11.66 | $11.14 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022before the open | $2.86B | – | $7.47 | $9.77 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022before the open | $2.97B | – | $8.61 | $11.49 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 4, 2022before the open | $4.95B | – | $19.69 | $23.72 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $3.45B | – | $14.33 | $15.37 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 11, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Regeneron Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| GAAP gross margin on net product salesGAAP | FY2026 | 80% | 78% – 79% | Raised | Oct 30, 2026 |
| Non-GAAP gross margin on net product sales (a)non-GAAP | FY2026 | 86% | 84% – 85% | Raised | Oct 30, 2026 |
| Capital expenditures | FY2026 | $1.05B – $1.10B | $1.03B – $1.10B | Raised | Oct 30, 2026 |
| GAAP effective tax rateGAAP | FY2026 | 14% | 13% – 14% | Raised | Oct 30, 2026 |
| GAAP R&DGAAP | FY2026 | $6.60B – $6.74B | $6.50B – $6.64B | Raised | Oct 30, 2026 |
| GAAP R&D expenseGAAP | FY2026 | $6.50B | – | New | Jan 12, 2026 |
| GAAP SG&AGAAP | FY2026 | $2.73B – $2.86B | $2.83B – $2.96B | Lowered | Oct 30, 2026 |
| Non-GAAP effective tax rate (a)non-GAAP | FY2026 | 15% | 14% – 15% | Raised | Oct 30, 2026 |
| Non-GAAP R&D (a)non-GAAP | FY2026 | $6.05B – $6.15B | $5.95B – $6.05B | Raised | Oct 30, 2026 |
| Non-GAAP R&D spendnon-GAAP | FY2026 | $7.00B | – | New | Jan 12, 2026 |
| Non-GAAP SG&A (a)non-GAAP | FY2026 | $2.40B – $2.50B | $2.50B – $2.60B | Lowered | Oct 30, 2026 |
Guidance history
Every forecast Regeneron Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 30, 2026 | Capital expenditures | FY2026 | $1.05B – $1.10B | Raised |
| Oct 30, 2026 | GAAP gross margin on net product sales | FY2026 | 80% | Raised |
| Oct 30, 2026 | Non-GAAP gross margin on net product sales (a) | FY2026 | 86% | Raised |
| Oct 30, 2026 | GAAP R&D | FY2026 | $6.60B – $6.74B | Raised |
| Oct 30, 2026 | GAAP SG&A | FY2026 | $2.73B – $2.86B | Lowered |
| Oct 30, 2026 | Non-GAAP SG&A (a) | FY2026 | $2.40B – $2.50B | Lowered |
| Oct 30, 2026 | Non-GAAP R&D (a) | FY2026 | $6.05B – $6.15B | Raised |
| Oct 30, 2026 | GAAP effective tax rate | FY2026 | 14% | Raised |
| Oct 30, 2026 | Non-GAAP effective tax rate (a) | FY2026 | 15% | Raised |
| Jul 30, 2026 | Capital expenditures | FY2026 | $1.03B – $1.10B | Lowered |
| Jul 30, 2026 | GAAP gross margin on net product sales | FY2026 | 78% – 79% | Raised |
| Jul 30, 2026 | Non-GAAP gross margin on net product sales (a) | FY2026 | 84% – 85% | Raised |
| Jul 30, 2026 | GAAP effective tax rate | FY2026 | 13% – 14% | Raised |
| Jul 30, 2026 | Non-GAAP effective tax rate (a) | FY2026 | 14% – 15% | Raised |
| Jul 30, 2026 | GAAP R&D | FY2026 | $6.50B – $6.64B | Raised |
| Jul 30, 2026 | GAAP SG&A | FY2026 | $2.83B – $2.96B | Lowered |
| Jul 30, 2026 | Non-GAAP R&D (a) | FY2026 | $5.95B – $6.05B | Raised |
| Jul 30, 2026 | Non-GAAP SG&A (a) | FY2026 | $2.50B – $2.60B | Lowered |
| Apr 29, 2026 | Capital expenditures | FY2026 | $1.10B – $1.20B | Lowered |
| Apr 29, 2026 | GAAP gross margin on net product sales | FY2026 | 77% – 78% | Lowered |
| Apr 29, 2026 | Non-GAAP gross margin on net product sales (a) | FY2026 | 83% – 84% | Reaffirmed |
| Apr 29, 2026 | GAAP effective tax rate | FY2026 | 12% – 14% | Reaffirmed |
| Apr 29, 2026 | Non-GAAP effective tax rate (a) | FY2026 | 13% – 15% | Reaffirmed |
| Apr 29, 2026 | GAAP R&D | FY2026 | $6.45B – $6.68B | Raised |
| Apr 29, 2026 | GAAP SG&A | FY2026 | $2.86B – $3.04B | Lowered |
| Apr 29, 2026 | Non-GAAP R&D (a) | FY2026 | $5.90B – $6.10B | Raised |
| Apr 29, 2026 | Non-GAAP SG&A (a) | FY2026 | $2.50B – $2.65B | Lowered |
| Jan 30, 2026 | Capital expenditures ** | FY2026 | $1.10B – $1.30B | New |
| Jan 30, 2026 | GAAP gross margin on net product sales | FY2026 | 79% – 80% | New |
| Jan 30, 2026 | Non-GAAP gross margin on net product sales (a) | FY2026 | 83% – 84% | New |
| Jan 30, 2026 | GAAP effective tax rate | FY2026 | 12% – 14% | New |
| Jan 30, 2026 | Non-GAAP effective tax rate (a) | FY2026 | 13% – 15% | New |
| Jan 30, 2026 | GAAP R&D | FY2026 | $6.45B – $6.68B | New |
| Jan 30, 2026 | GAAP SG&A | FY2026 | $2.86B – $3.04B | Lowered |
| Jan 30, 2026 | Non-GAAP R&D (a) | FY2026 | $5.90B – $6.10B | New |
| Jan 30, 2026 | Non-GAAP SG&A (a) | FY2026 | $2.50B – $2.65B | Lowered |
| Jan 12, 2026 | GAAP R&D expense | FY2026 | $6.50B | New |
| Jan 12, 2026 | Non-GAAP R&D spend | FY2026 | $7.00B | New |
| Oct 28, 2025 | Capital expenditures *** | FY2025 | $850.00M – $890.00M | Lowered |
| Oct 28, 2025 | GAAP gross margin on net product sales | FY2025 | 82% | Lowered |
| Oct 28, 2025 | Non-GAAP gross margin on net product sales (a) | FY2025 | 86% | Lowered |
| Oct 28, 2025 | GAAP effective tax rate | FY2025 | 14% | Raised |
| Oct 28, 2025 | Non-GAAP effective tax rate (a) | FY2025 | 12% | Narrowed |
| Oct 28, 2025 | GAAP R&D | FY2025 | $5.68B – $5.75B | Raised |
| Oct 28, 2025 | GAAP SG&A ** | FY2025 | $2.78B – $2.85B | Lowered |
| Oct 28, 2025 | Non-GAAP R&D (a) | FY2025 | $5.15B – $5.20B | Raised |
| Oct 28, 2025 | Non-GAAP SG&A (a)** | FY2025 | $2.40B – $2.45B | Lowered |
| Aug 1, 2025 | Capital expenditures | FY2025 | $880.00M – $950.00M | New |
| Aug 1, 2025 | GAAP gross margin on net product sales | FY2025 | 83% | New |
| Aug 1, 2025 | Non-GAAP gross margin on net product sales | FY2025 | 86% | New |
| Aug 1, 2025 | GAAP effective tax rate | FY2025 | 11% – 13% | New |
| Aug 1, 2025 | Non-GAAP effective tax rate | FY2025 | 11% – 13% | New |
| Aug 1, 2025 | COCM | FY2025 | $1.00B – $1.05B | New |
| Aug 1, 2025 | GAAP R&D | FY2025 | $5.66B – $5.79B | New |
| Aug 1, 2025 | GAAP SG&A | FY2025 | $2.81B – $2.94B | Lowered |
| Aug 1, 2025 | Non-GAAP R&D | FY2025 | $5.10B – $5.20B | New |
| Aug 1, 2025 | Non-GAAP SG&A | FY2025 | $2.45B – $2.55B | Lowered |
| Apr 29, 2025 | Capital expenditures | FY2025 | $850.00M – $950.00M | Lowered |
| Apr 29, 2025 | GAAP gross margin on net product sales | FY2025 | 83% – 84% | Lowered |
| Apr 29, 2025 | Non-GAAP gross margin on net product sales | FY2025 | 86% – 87% | Lowered |
| Apr 29, 2025 | GAAP effective tax rate | FY2025 | 9% – 11% | Reaffirmed |
| Apr 29, 2025 | Non-GAAP effective tax rate | FY2025 | 11% – 13% | Reaffirmed |
| Apr 29, 2025 | COCM | FY2025 | $1.00B – $1.15B | Reaffirmed |
| Apr 29, 2025 | GAAP R&D | FY2025 | $5.56B – $5.80B | Raised |
| Apr 29, 2025 | GAAP SG&A | FY2025 | $2.91B – $3.10B | Lowered |
| Apr 29, 2025 | Non-GAAP R&D | FY2025 | $5.00B – $5.20B | Raised |
| Apr 29, 2025 | Non-GAAP SG&A | FY2025 | $2.55B – $2.70B | Lowered |
| Feb 4, 2025 | Capital expenditures | FY2025 | $850.00M – $975.00M | New |
| Feb 4, 2025 | GAAP gross margin on net product sales | FY2025 | 84% – 85% | New |
| Feb 4, 2025 | Non-GAAP gross margin on net product sales | FY2025 | 87% – 88% | New |
| Feb 4, 2025 | GAAP effective tax rate | FY2025 | 9% – 11% | New |
| Feb 4, 2025 | Non-GAAP effective tax rate | FY2025 | 11% – 13% | New |
| Feb 4, 2025 | COCM | FY2025 | $1.00B – $1.15B | New |
| Feb 4, 2025 | GAAP R&D | FY2025 | $5.56B – $5.80B | New |
| Feb 4, 2025 | GAAP SG&A | FY2025 | $2.91B – $3.10B | Lowered |
| Feb 4, 2025 | Non-GAAP R&D | FY2025 | $5.00B – $5.20B | New |
| Feb 4, 2025 | Non-GAAP SG&A | FY2025 | $2.55B – $2.70B | Lowered |
| Oct 31, 2024 | Capital expenditures * | FY2024 | $700.00M – $740.00M | Lowered |
| Oct 31, 2024 | GAAP gross margin on net product sales (d) | FY2024 | 86% | Reaffirmed |
| Oct 31, 2024 | Non-GAAP gross margin on net product sales (a)(d) | FY2024 | 89% | Reaffirmed |
| Oct 31, 2024 | GAAP effective tax rate | FY2024 | 8% – 9% | Reaffirmed |
| Oct 31, 2024 | Non-GAAP effective tax rate (a) | FY2024 | 10% – 11% | Reaffirmed |
| Oct 31, 2024 | COCM (e)* | FY2024 | $860.00M – $900.00M | Narrowed |
| Oct 31, 2024 | GAAP R&D | FY2024 | $5.06B – $5.15B | Raised |
| Oct 31, 2024 | GAAP SG&A | FY2024 | $2.93B – $3.02B | Lowered |
| Oct 31, 2024 | Non-GAAP R&D (a) | FY2024 | $4.53B – $4.58B | Raised |
| Oct 31, 2024 | Non-GAAP SG&A (a) | FY2024 | $2.55B – $2.60B | Lowered |
| Aug 1, 2024 | Capital expenditures | FY2024 | $750.00M – $820.00M | Lowered |
| Aug 1, 2024 | GAAP gross margin on net product sales | FY2024 | 86% | Lowered |
| Aug 1, 2024 | Non-GAAP gross margin on net product sales | FY2024 | 89% | Lowered |
| Aug 1, 2024 | GAAP effective tax rate | FY2024 | 8% – 9% | Raised |
| Aug 1, 2024 | Non-GAAP effective tax rate | FY2024 | 10% – 11% | Lowered |
| Aug 1, 2024 | COCM | FY2024 | $850.00M – $910.00M | Reaffirmed |
| Aug 1, 2024 | GAAP R&D | FY2024 | $5.02B – $5.17B | Raised |
| Aug 1, 2024 | GAAP SG&A | FY2024 | $2.92B – $3.06B | Lowered |
| Aug 1, 2024 | Non-GAAP R&D | FY2024 | $4.50B – $4.60B | Raised |
| Aug 1, 2024 | Non-GAAP SG&A | FY2024 | $2.55B – $2.65B | Lowered |
| May 2, 2024 | Capital expenditures | FY2024 | $780.00M – $880.00M | Lowered |
| May 2, 2024 | GAAP gross margin on net product sales | FY2024 | 86% – 88% | Reaffirmed |
| May 2, 2024 | Non-GAAP gross margin on net product sales | FY2024 | 89% – 91% | Reaffirmed |
| May 2, 2024 | GAAP effective tax rate | FY2024 | 7% – 9% | Lowered |
| May 2, 2024 | Non-GAAP effective tax rate | FY2024 | 10% – 12% | Reaffirmed |
| May 2, 2024 | COCM | FY2024 | $850.00M – $910.00M | Reaffirmed |
| May 2, 2024 | GAAP R&D | FY2024 | $4.92B – $5.17B | Raised |
| May 2, 2024 | GAAP SG&A | FY2024 | $2.94B – $3.09B | Lowered |
| May 2, 2024 | Non-GAAP R&D | FY2024 | $4.40B – $4.60B | Raised |
| May 2, 2024 | Non-GAAP SG&A | FY2024 | $2.55B – $2.65B | Lowered |
| Feb 2, 2024 | Capital expenditures | FY2024 | $825.00M – $950.00M | New |
| Feb 2, 2024 | GAAP gross margin on net product sales | FY2024 | 86% – 88% | New |
| Feb 2, 2024 | Non-GAAP gross margin on net product sales | FY2024 | 89% – 91% | New |
| Feb 2, 2024 | GAAP effective tax rate | FY2024 | 8% – 10% | New |
| Feb 2, 2024 | Non-GAAP effective tax rate | FY2024 | 10% – 12% | New |
| Feb 2, 2024 | COCM | FY2024 | $850.00M – $910.00M | New |
| Feb 2, 2024 | GAAP R&D | FY2024 | $4.82B – $5.07B | New |
| Feb 2, 2024 | GAAP SG&A | FY2024 | $2.89B – $3.09B | Lowered |
| Feb 2, 2024 | Non-GAAP R&D | FY2024 | $4.30B – $4.50B | New |
| Feb 2, 2024 | Non-GAAP SG&A | FY2024 | $2.50B – $2.65B | Lowered |
| Nov 2, 2023 | Capital expenditures | FY2023 | $660.00M – $700.00M | Lowered |
| Nov 2, 2023 | GAAP gross margin on net product sales | FY2023 | 87% – 88% | Lowered |
| Nov 2, 2023 | Non-GAAP gross margin on net product sales | FY2023 | 89% – 90% | Lowered |
| Nov 2, 2023 | GAAP effective tax rate | FY2023 | 8% – 9% | Reaffirmed |
| Nov 2, 2023 | Non-GAAP effective tax rate | FY2023 | 10% – 11% | Reaffirmed |
| Nov 2, 2023 | COCM | FY2023 | $840.00M – $880.00M | Raised |
| Nov 2, 2023 | GAAP R&D | FY2023 | $4.37B – $4.46B | Raised |
| Nov 2, 2023 | GAAP SG&A | FY2023 | $2.59B – $2.69B | Lowered |
| Nov 2, 2023 | Non-GAAP R&D | FY2023 | $3.88B – $3.93B | Raised |
| Nov 2, 2023 | Non-GAAP SG&A | FY2023 | $2.21B – $2.27B | Lowered |
| Aug 3, 2023 | Capital expenditures | FY2023 | $760.00M – $830.00M | Lowered |
| Aug 3, 2023 | GAAP gross margin on net product sales | FY2023 | 87% – 89% | Reaffirmed |
| Aug 3, 2023 | Non-GAAP gross margin on net product sales | FY2023 | 89% – 91% | Reaffirmed |
| Aug 3, 2023 | GAAP effective tax rate | FY2023 | 8% – 9% | Lowered |
| Aug 3, 2023 | Non-GAAP effective tax rate | FY2023 | 10% – 11% | Lowered |
| Aug 3, 2023 | COCM | FY2023 | $820.00M – $880.00M | Reaffirmed |
| Aug 3, 2023 | GAAP R&D | FY2023 | $4.32B – $4.46B | Raised |
| Aug 3, 2023 | GAAP SG&A | FY2023 | $2.54B – $2.68B | Lowered |
| Aug 3, 2023 | Non-GAAP R&D | FY2023 | $3.83B – $3.93B | Raised |
| Aug 3, 2023 | Non-GAAP SG&A | FY2023 | $2.18B – $2.28B | Lowered |
| May 4, 2023 | Capital expenditures | FY2023 | $800.00M – $900.00M | Lowered |
| May 4, 2023 | GAAP gross margin on net product sales | FY2023 | 87% – 89% | Lowered |
| May 4, 2023 | Non-GAAP gross margin on net product sales | FY2023 | 89% – 91% | Lowered |
| May 4, 2023 | GAAP effective tax rate | FY2023 | 8% – 10% | Lowered |
| May 4, 2023 | Non-GAAP effective tax rate | FY2023 | 10% – 12% | Lowered |
| May 4, 2023 | COCM | FY2023 | $820.00M – $880.00M | Raised |
| May 4, 2023 | GAAP R&D | FY2023 | $4.23B – $4.47B | Raised |
| May 4, 2023 | GAAP SG&A | FY2023 | $2.49B – $2.68B | Lowered |
| May 4, 2023 | Non-GAAP R&D | FY2023 | $3.73B – $3.93B | Raised |
| May 4, 2023 | Non-GAAP SG&A | FY2023 | $2.13B – $2.28B | Lowered |
| Feb 3, 2023 | Capital expenditures | FY2023 | $825.00M – $950.00M | New |
| Feb 3, 2023 | GAAP gross margin on net product sales | FY2023 | 88% – 90% | New |
| Feb 3, 2023 | Non-GAAP gross margin on net product sales | FY2023 | 90% – 92% | New |
| Feb 3, 2023 | GAAP effective tax rate | FY2023 | 10% – 12% | New |
| Feb 3, 2023 | Non-GAAP effective tax rate | FY2023 | 11% – 13% | New |
| Feb 3, 2023 | COCM | FY2023 | $720.00M – $800.00M | New |
| Feb 3, 2023 | GAAP R&D | FY2023 | $4.20B – $4.44B | New |
| Feb 3, 2023 | GAAP SG&A | FY2023 | $2.46B – $2.65B | Lowered |
| Feb 3, 2023 | Non-GAAP R&D | FY2023 | $3.73B – $3.93B | New |
| Feb 3, 2023 | Non-GAAP SG&A | FY2023 | $2.13B – $2.28B | Lowered |
| Nov 3, 2022 | Capital expenditures | FY2022 | $580.00M – $615.00M | Lowered |
| Nov 3, 2022 | Gross margin on net product sales | FY2022 | 90.5% – 91% | Raised |
| Nov 3, 2022 | Gross margin on net product sales | FY2022 | 92.5% – 93% | Raised |
| Nov 3, 2022 | Effective tax rate | FY2022 | 12% – 13% | Reaffirmed |
| Nov 3, 2022 | Effective tax rate | FY2022 | 13% – 14% | Reaffirmed |
| Nov 3, 2022 | R&D | FY2022 | $3.52B – $3.60B | Raised |
| Nov 3, 2022 | SG&A | FY2022 | $2.01B – $2.09B | Lowered |
| Nov 3, 2022 | COCM | FY2022 | $710.00M – $740.00M | Lowered |
| Nov 3, 2022 | Other operating (income) expense, net | FY2022 | -$85.00M | Lowered |
| Nov 3, 2022 | R&D | FY2022 | $3.11B – $3.17B | Raised |
| Nov 3, 2022 | SG&A | FY2022 | $1.76B – $1.82B | Lowered |
| Aug 3, 2022 | Capital expenditures | FY2022 | $620.00M – $670.00M | Lowered |
| Aug 3, 2022 | Effective tax rate | FY2022 | 12% – 13% | Raised |
| Aug 3, 2022 | Effective tax rate | FY2022 | 13% – 14% | Raised |
| Aug 3, 2022 | R&D | FY2022 | $3.49B – $3.66B | Raised |
| Aug 3, 2022 | SG&A | FY2022 | $1.99B – $2.11B | Lowered |
| Aug 3, 2022 | COCM | FY2022 | $710.00M – $760.00M | Lowered |
| Aug 3, 2022 | Other operating (income) expense, net | FY2022 | -$60.00M – -$40.00M | Lowered |
| Aug 3, 2022 | R&D | FY2022 | $3.10B – $3.24B | Raised |
| Aug 3, 2022 | SG&A | FY2022 | $1.74B – $1.84B | Lowered |
| May 4, 2022 | Capital expenditures | FY2022 | $630.00M – $700.00M | Lowered |
| May 4, 2022 | Gross margin on net product sales | FY2022 | 89% – 91% | Reaffirmed |
| May 4, 2022 | Gross margin on net product sales | FY2022 | 90% – 92% | Reaffirmed |
| May 4, 2022 | Effective tax rate (ETR) | FY2022 | 11% – 13% | Lowered |
| May 4, 2022 | Effective tax rate (ETR) | FY2022 | 12% – 14% | Lowered |
| May 4, 2022 | R&D | FY2022 | $3.27B – $3.50B | Raised |
| May 4, 2022 | SG&A | FY2022 | $1.89B – $2.03B | Lowered |
| May 4, 2022 | COCM | FY2022 | $750.00M – $830.00M | Lowered |
| May 4, 2022 | Other operating (income) expense, net | FY2022 | -$80.00M – -$60.00M | Lowered |
| May 4, 2022 | R&D | FY2022 | $2.90B – $3.10B | Raised |
| May 4, 2022 | SG&A | FY2022 | $1.65B – $1.77B | Lowered |
| Feb 4, 2022 | Capital expenditures | FY2022 | $650.00M – $730.00M | New |
| Feb 4, 2022 | Gross margin on net product sales | FY2022 | 89% – 91% | New |
| Feb 4, 2022 | Gross margin on net product sales | FY2022 | 90% – 92% | New |
| Feb 4, 2022 | Effective tax rate (ETR) | FY2022 | 12% – 14% | New |
| Feb 4, 2022 | Effective tax rate (ETR) | FY2022 | 13% – 15% | New |
| Feb 4, 2022 | R&D | FY2022 | $3.17B – $3.40B | New |
| Feb 4, 2022 | SG&A | FY2022 | $1.89B – $2.03B | Lowered |
| Feb 4, 2022 | COCM | FY2022 | $750.00M – $830.00M | Lowered |
| Feb 4, 2022 | Other operating (income) expense, net | FY2022 | -$80.00M – -$60.00M | Lowered |
| Feb 4, 2022 | R&D | FY2022 | $2.80B – $3.00B | New |
| Feb 4, 2022 | SG&A | FY2022 | $1.65B – $1.77B | Lowered |
| Nov 4, 2021 | Capital expenditures | FY2021 | $545.00M – $575.00M | New |
| Nov 4, 2021 | Gross margin on net product sales | FY2021 | 87.5% | New |
| Nov 4, 2021 | Gross margin on net product sales | FY2021 | 88% | New |
| Nov 4, 2021 | R&D | FY2021 | $2.85B – $2.92B | New |
| Nov 4, 2021 | SG&A | FY2021 | $1.76B – $1.83B | Lowered |
| Nov 4, 2021 | COCM | FY2021 | $670.00M – $700.00M | Lowered |
| Nov 4, 2021 | R&D | FY2021 | $2.55B – $2.60B | New |
| Nov 4, 2021 | SG&A | FY2021 | $1.56B – $1.61B | Lowered |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Regeneron Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results